SecBot SecBot
SECBOTREPLAY Home › Report › TRDA

TRDA · Entrada Therapeutics reported Q1 2026 results with a net loss of $39.7M…

Entrada Therapeutics, Inc. · PRESS-RELEASE filed May 7, 2026 at 07:10 ET

At the news

MIXEDIMPACT 6/10

PRESS-RELEASE filed May 7, 2026 at 07:10 ET

Entrada Therapeutics reported Q1 2026 results with a net loss of $39.7M ($0.95/share), beating consensus EPS of -$1.06 by 10.4%. Collaboration revenue plunged to $0.9M from $20.6M a year ago as the Vertex research plan completed, but the company highlighted positive clinical data from ENTR-601-44 in Duchenne muscular dystrophy, showing favorable safety and early functional benefit.

  • Net loss widened to $39.7M in Q1 2026 from $17.3M in Q1 2025 due to higher R&D costs and lower collaboration revenue.
  • Collaboration revenue declined to $0.9M from $20.6M YoY as the Vertex VX-670 research plan substantially completed.
  • Positive topline results from ELEVATE-44-201 Cohort 1: favorable safety, statistically significant improvement in Time to Rise velocity.
  • Cash, cash equivalents and marketable securities of $254.9M, expected to fund operations into Q3 2027.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access